Skip to content
naulon
Not checkedNot checked for notices yet.

Analysis of D-Dimer Level and Prothombin Time (PT) Activated Prothombin Thromboplastin (APTT) on Heparin Administration to COVID-19 Patients

Dela Yorike, Muhammad Rizki Kurniawan, Mohamad Syafaat

Indonesian Journal of Medical Laboratory Science and Technology · 2022

doi:10.33086/ijmlst.v4i1.2487 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Coronavirus is a dangerous pathogen that affects both humans and animals. Symptoms and indicators of COVID-19 infection include fever, cough, and shortness of breath, which are common in respiratory illnesses. COVID-19 has spread globally with high mortality and morbidity rates. Prothrombin Time (PT), Activated Prothrombin Thromboplastin (APTT), and D-Dimer parameters are blood tests to evaluate the coagulation status of COVID-19 patients, all these parameters increased in COVID-19 patients. This study aims at determininig the levels of D-Dimer, PT, and APTT in COVID-19 patients. Clinical and laboratory records were retrospectively reviewed from 100 cases of COVID-19 admitted to hospitals. This study used a a cross-sectional, descriptive, secondary data analysis design. The sample included patients from the Bhayangkara TK. I R.Said Sukanto Hospital between April-July 2021. The sample is a COVID-19 patient who was treated in the Intensive Care Unit (ICU), worsened, and given heparin. An independent variable is the administration of intravenous heparin at prophylactic doses. Dependent variables are D-Dimer, PT, and APTT values. The collected data is processed using Microsoft Office Excel and then being analyzed. D-Dimer, PT, and APTT levels in COVID-19 patients were initially high or increased after heparin administration decreased or became normal. In conclusion, there was a decrease in D-dimer levels, PT values, and APTT after administration of intravenous heparin at prophylactic doses.

Abstract licence: CC BY-SA

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.